Cargando…

Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients

Immune checkpoint inhibition represents an important therapeutic option for advanced melanoma patients. Results from clinical studies have shown that treatment with the PD-1 inhibitors Pembrolizumab and Nivolumab provides improved response and survival rates. Moreover, combining Nivolumab with the C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schaefer, Anne, Sachpekidis, Christos, Diella, Francesca, Doerks, Anja, Kratz, Anne-Sophie, Meisel, Christian, Jackson, David B., Soldatos, Theodoros G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226447/ https://www.ncbi.nlm.nih.gov/pubmed/32325840 http://dx.doi.org/10.3390/cancers12041008

Ejemplares similares

Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar
por: Sachpekidis, Christos, et al.
Publicado: (2019)

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018)

Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2019)

Adverse Event Circumstances and the Case of Drug Interactions
por: Soldatos, Theodoros G., et al.
Publicado: (2019)

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
por: de Filette, Jeroen, et al.
Publicado: (2016)

In Silico Profiling of Clinical Phenotypes for Human Targets Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018)

Association Between Serotonin Syndrome and Second‐Generation Antipsychotics via Pharmacological Target‐Adverse Event Analysis
por: Racz, Rebecca, et al.
Publicado: (2018)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
por: Grimaldi, Antonio Maria, et al.
Publicado: (2015)

Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting
por: Schotland, Peter, et al.
Publicado: (2020)

Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports
por: Soldatos, Theodoros G., et al.
Publicado: (2022)

Pembrolizumab‐caused polyradiculoneuropathy as an immune‐related adverse event
por: Kurashige, Takashi, et al.
Publicado: (2021)

Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab
por: Lima, Gian, et al.
Publicado: (2019)

A case study of a patient‐centered reverse translational systems‐based approach to understand adverse event profiles in drug development
por: Kim, Sarah, et al.
Publicado: (2022)

Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts
por: Larribère, Lionel, et al.
Publicado: (2018)

Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab
por: Shah, N., et al.
Publicado: (2019)

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
por: Eun, Yeonghee, et al.
Publicado: (2019)

Spotlight on pembrolizumab in the treatment of advanced melanoma
por: Rajakulendran, Thanashan, et al.
Publicado: (2015)

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
por: Almutairi, Abdulaali R., et al.
Publicado: (2020)

Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma
por: Paepegaey, Anne-Cécile, et al.
Publicado: (2017)

IgA Nephropathy that Developed as an Immune-related Adverse Event of Pembrolizumab Complicated with Interstitial Nephritis
por: Mitarai, Yuki, et al.
Publicado: (2021)

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma
por: Barnhart, Carrie
Publicado: (2015)

Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma
por: Dollin, Yonatan, et al.
Publicado: (2020)

Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab
por: Du Four, Stephanie, et al.
Publicado: (2018)

Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events
por: Müller, Benjamin, et al.
Publicado: (2023)

STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations
por: Kim, James, et al.
Publicado: (2020)

New developments in the management of advanced melanoma – role of pembrolizumab
por: Improta, Giuseppina, et al.
Publicado: (2015)

Challenging the standard of care in advanced melanoma: focus on pembrolizumab
por: Abdul-Karim, Raghad M, et al.
Publicado: (2017)

Pembrolizumab as first-line treatment for metastatic uveal melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Disseminated blastomycosis in a patient on pembrolizumab for metastatic melanoma
por: Ferguson, Ian, et al.
Publicado: (2019)

Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma
por: Bari, Omar, et al.
Publicado: (2017)

Pembrolizumab for the treatment of uveal melanoma: A case series
por: Jansen, Yanina Jeanne Leona, et al.
Publicado: (2020)

Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment
por: Larsen, Frederik Uttenthal, et al.
Publicado: (2019)

Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review
por: Rizzetto, Giulio, et al.
Publicado: (2023)

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
por: Noguchi, Susumu, et al.
Publicado: (2020)

Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus
por: Jono, Misato, et al.
Publicado: (2019)

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
por: Möhn, Nora, et al.
Publicado: (2019)

Pembrolizumab-Induced Hypophysitis With Isolated Adrenocorticotropic Hormone (ACTH) Deficiency: A Rare Immune-Mediated Adverse Event
por: Doodnauth, Andrew V, et al.
Publicado: (2021)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

A Review of Immune-Mediated Adverse Events in Melanoma
por: Kennedy, Lucy Boyce, et al.
Publicado: (2019)

Complications and adverse events of plaque brachytherapy for ocular melanoma
por: Peddada, Krishi V., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_omd9pe5tnm1gui1vhavgdhsu1e